Australian certification for Ind-Swift

Ind-Swift Laboratories Ltd has obtained a therapeutic goods administration (TGA) certification from the Australian Common Wealth Department of Health and Ageing for its manufacturing facility for the 1.18 bn drug Clarithromycin.

Ind-Swift Laboratories is one of the largest manufacturers of Clarithromycin in the world, with 30-33 per cent of the world's capacity for this drug.

The Australian Common Wealth Department of Health and Ageing has recommended that "the company complies with the requirement of the Australian Code of Good Manufacturing Practice for medicinal products, for the range of products to be supplied to Australia".

Ind-Swift's manufacturing facility at Derabassi in Punjab is one of the company's biggest manufacturing facilities.

The facility has eight dedicated blocks to manufacture high-class API and advanced intermediates for regulated markets. Another facility is situated in the tax exempted zone of Jammu in (Jammu & Kashmir) where API for the domestic market is manufactured.

"It is a significant achievement as the company is focusing on the regulated markets for its growth. The TGA certification will leverage the company's intrinsic potential and place it at par with the other leading players in the industry," said V K Mehta, joint managing director, Ind-Swift Laboratories.

The company's facilities already have WHO and Iranian Government certification. Ind-Swift has filed 7 DMFs in the US and several DMFs with the European authorities for its active pharmaceutical ingredients.

Its subsidiary in the US is already forging contracts with leading players for supply of its products.